The single-point insulin sensitivity estimator (SPISE) index is a strong predictor of abnormal glucose metabolism in overweight/obese children: a long-term follow-up study

I. Barchetta · S. Dule · L. Bertocci · F. A. Cimini · F. Sentinelli · D. Bailetti · G. Marini · A. Barbonetti · S. Loche · E. Cossu · M. G. Cavallo · M. G. Baroni

Received: 21 May 2021 / Accepted: 7 June 2021 / Published online: 17 June 2021
© The Author(s) 2021

Abstract

Purpose To investigate the relationship between the single-point insulin sensitivity estimator (SPISE) index, an insulin sensitivity indicator validated in adolescents and adults, and metabolic profile in overweight/obese children, and to evaluate whether basal SPISE is predictive of impaired glucose regulation (IGR) development later in life.

Methods The SPISE index (= 600 × HDL^{0.185}/Triglycerides^{0.2} × BMI^{1.338}) was calculated in 909 overweight/obese children undergoing metabolic evaluations at University of Cagliari, Italy, and in 99 normal-weight, age-, sex-comparable children, selected as a reference group, together with other insulin-derived indicators of insulin sensitivity/resistance. 200 overweight/obese children were followed-up for 6.5 [3.5–10] years, data were used for longitudinal retrospective investigations.

Results At baseline, 96/909 (11%) overweight/obese children had IGR; in this subgroup, SPISE was significantly lower than in normo-glycaemic youths (6.3 ± 1.7 vs. 7 ± 1.6, p < 0.001). The SPISE index correlated positively with the insulin sensitivity index (ISI) and the disposition index (DI), negatively with age, blood pressure, HOMA-IR, basal and 120 min blood glucose and insulin (all p values < 0.001). A correlation between SPISE, HOMA-IR and ISI was also reported in normal-weight children. At the 6.5-year follow-up, lower basal SPISE—but not ISI or HOMA-IR—was an independent predictor of IGR development (OR = 3.89(1.65–9.13), p = 0.002; AUROC: 0.82(0.72–0.92), p < 0.001).

Conclusion In children, low SPISE index is significantly associated with metabolic abnormalities and predicts the development of IGR in life.

Keywords Childhood obesity · Insulin resistance · Impaired glucose regulation · Insulin-sensitivity index · SPISE · Screening

Introduction

Overweight and obesity in childhood are conditions epidemiologically spread worldwide, and the dramatic increase of their incidence in the last decades has become a relevant public health issue around the world [1]. Data show that 17.9% of European children were overweight or obese during the period 2006–2016. The prevalence estimate of obesity was 5.3%, with highest values reported in the Southern European countries [2]. The increasing prevalence in children comes with escalations in both current childhood and future adult- hood morbidity and mortality [3], but also in concomitant costs [4].

Early onset obesity is an independent risk factor for the development of insulin resistance and type 2 diabetes (T2D) [5], and insulin resistance represents the most common
metabolic disorder associated with obesity [6, 7]. Insulin resistance and T2D are well known independent risk factors for cardiovascular diseases [8].

The pathogenesis of insulin resistance in children is a multi-factorial process and obesity is the most prevalent risk factor [9]. Also genetic predisposition [10], gestational diabetes [11], children born small for gestational age (SGA) [12], rapid post-natal weight gain [13], premature birth [14] and smoking during pregnancy [15], increase the risk of insulin resistance during childhood.

Not all obese children are insulin resistant, and insulin resistance can also occur in non-obese children [16]. The prevalence of insulin resistance in obese children varies from 33.2 to 52.1% [17–19], depending on the method and cut-off used to define insulin resistance.

Indeed, the identification of accurate tools for risk stratification in obese/overweight children is a crucial step for designing strategies to prevent metabolic diseases and their complications later in life. However, standards for assessing insulin resistance in children in the clinical setting are still lacking, and insulin-derived indexes of insulin resistance/sensitivity are affected by methodological issues, such as the poor standardization of insulin measurement [16, 20–22]. Among the non-insulin-derived indices, the single-point insulin sensitivity estimator (SPISE) index is a lipids and BMI-based index of insulin sensitivity that showed better accuracy than other indicators, such as its forerunner TG/HDL-C ratio and HOMA-IR, in the prediction of metabolic syndrome and has been recently validated in adolescents and adults [23, 24]. To date, the usefulness of the SPISE index has not been investigated in a pediatric population. Furthermore, no prospective data exists on the predictive value of this parameter on insulin resistance and glucose abnormalities.

Therefore, aims of this study were (i) to investigate the relationship between the SPISE index, glyco-metabolic profile and insulin sensitivity in a large population of children, with and without obesity, and (ii) to evaluate whether basal SPISE is predictive of the development of impaired glucose metabolism later in life.

Research design and methods

Study population

For the purposes of this study, we carried out a cross-sectional and a longitudinal retrospective investigation.

For the cross-sectional phase of this study, we analysed the SPISE index from data obtained in 909 overweight or obese children (median age [interquartile range]: 10 [8–13] years) consecutively recruited at the Paediatric Endocrine outpatient clinics of the Paediatric Hospital for Microcitaemia, Cagliari, Italy. Study participants were selected among all those referring to the clinic for the presence of excess bodyweight, as for indication of the general practitioner; main exclusion criteria were the presence of endocrine disorders or genetic syndromes, including syndromic obesity. After visit, all children with overweight or obesity were instructed to follow an educational program including dietary and lifestyle modifications.

To provide a reference range in children with normal metabolic status, the SPISE index was also calculated in 99 normal-weight healthy children (median age [interquartile range]: 11 [9–12.9] years) with age and sex distribution comparable to the first cohort. These normal-weight children, without any endocrine, cardiovascular, gastrointestinal or renal disorder, were recruited in the same clinical setting and selected among those referring to the Paediatric outpatients’ clinic for undergoing routine clinical assessment. The enrolment of the whole study population occurred between May 2007 and May 2010.

200 out of 909 overweight/obese children were followed-up between 2013 and 2016, with a median (range) follow-up duration of 6.5 (3.5–10) years, and data collected were used for the longitudinal investigation (see reference [25] for description of this cohort).

Clinical and biochemical evaluations

At the baseline, all the study participants (n = 1008) underwent medical history collection, clinical examination and fasting blood sampling. Children with fasting blood glucose less than 126 mg/dl underwent oral glucose tolerance test (OGTT) at both the baseline and follow-up visit, following clinical recommendations for children (1.75 g of glucose administered per kg bodyweight, up to 75 g) [26]. Blood glucose and insulin concentrations were measured at the baseline and after 120 min from the oral glucose load. The presence of an abnormal glucose metabolism (AGM), in terms of impaired glucose regulation (IGR: impaired fasting glucose, IFG, impaired glucose tolerance, IGT) or diabetes mellitus, was diagnosed according to criteria from the ADA Standards of Medical Care in Diabetes 2021 [27].

Systolic and diastolic blood pressure (SBP, DBP, mmHg) was measured after 10-min rest and the average value of three measurements was recorded for the analysis.

Overweight, obesity and standard deviation score body mass index (SDS–BMI) were defined according to the Italian growth charts for height, weight and BMI in people aged 2–20 years, more than one standard deviation (SD) of BMI defined overweight and more than 2 SD defined obesity [28].

Study participants were classified as pre-pubertal or pubertal according to the Tanner stage for pubertal development (pre-puberal, for Tanner’s stage I: boys with pubic hair and gonadal stage I, girls with pubic hair stage and breast
concentrations expressed in mg/dL and BMI as kg/m² [23] with fasting HDL-C and Triglycerides

and breast stage ≥ II) [29] age, as appropriate. Skewed variables were log-transformed

deviation (SD), median (interquartile range, IQR) or percent-

package, version 25.0. Values are shown as mean ± standard

All the analyses were performed using the SPSS statistical

procedures.

Ethics Committee and conducted in conformance with the

Helsinki Declaration. Informed written consent was obtained

This subgroup, the SPISE index negatively correlated with

The SPISE did not associate with sex at the univariate logis-
tic analysis (β = −2.2, p = 0.29) was observed.

Ethics standards

The study protocol was reviewed and approved by the local

Ethics Committee and conducted in conformance with the

Helsinki Declaration. Informed written consent was obtained

from the children or their legal guardians before all the study

procedures.

Statistics

All the analyses were performed using the SPSS statistical
package, version 25.0. Values are shown as mean ± standard
deviation (SD), median (interquartile range, IQR) or percent-
age, as appropriate. Skewed variables were log-transformed

before the analyses. Differences between two independent
groups were compared by Student’s T test for continuous

variables and by χ² test for categorical parameters. Correla-
tions were estimated by Pearson’s and Spearman’s tests, in
relation to the type and distribution of the variables. Univari-
ate regression analyses were performed to test the associa-
tion between binomial (i.e. sex, AGM…) and continuous

variables.

The predictive value of SPISE value at the baseline for

the onset of abnormal glucose metabolism (IFG and/or IGT

or T2D) at the follow-up was estimated by multiple logistic

regression analysis adjusted for age, sex, fasting and 120 min

glucose and insulin levels at the baseline. An adjusted area

under receiver-operating characteristic curve (AUROC) of

SPISE for AGM, with 95% confidence interval (C.I.), was

also calculated controlling for the same covariates. P values

< 0.05 were considered statistically significant with a

C.I. of 95%.

Results

Baseline assessments

At baseline, overweight/obese children (n = 909, mean ± SD
age: 10.3 ± 3.2 years; M/F 433/476, mean ± SD BMI:
27.4 ± 4.4 kg/m²; SDS BMI: 2.05 ± 0.4) had mean ± SD
SPISE of 6.9 ± 1.6.

In these subjects, the prevalence of alterations of glu-
cose metabolism at baseline was almost 11% (96 out of
909 subjects). Children with IGR had significantly lower
SPISE than those with normal glucose tolerance (mean ± SD
SPISE: 6.3 ± 1.7 vs. 7 ± 1.6, p < 0.001). In our study popula-
tion, triglycerides, AST, ALT, blood insulin, DI, HOMA-IR,
HOMA-β%, ISI, SPISE had a skewed distribution; charac-
teristics of the whole study population and according to the

glucose tolerance profile are illustrated in Table 1.

At the bivariate analysis, the SPISE index positively cor-
related with the ISI and DI whereas an inverse association
was found between SPISE and age, blood pressure, HOMA-
IR, basal and 120 min blood glucose and insulin (Table 2).
The SPISE did not associate with sex at the univariate logistic
analysis (β coefficient = 0.79, p = 0.19).

The existence of a significant association between SPISE
and insulin-derived indexes of insulin sensitivity (ISI),
resistance (HOMA-IR) and secretion (HOMA-β%) was
also detected in a cohort of 99 normal-weight metaboli-
cally healthy children (ISI: r = 0.55, p < 0.001; HOMA-IR:
r = −0.44, p = 0.002; HOMA-β %: r = −0.4, p = 0.006). In
this subgroup, the SPISE index negatively correlated with
age (r = −0.43, p < 0.001) and FSI (r = −0.47, p < 0.001); no
association with FBG (r = −0.08, p = 0.47) or sex (β = −2.2,
p = 0.29) was observed.
Finally, the SPISE index strongly correlated with ISI (A; \( r = 0.49, p < 0.001 \)) and HOMA-IR (B; \( r = -0.41, p < 0.001 \)) in the whole study population of 1008 children belonging to different BMI classes (Fig. 1a, b).

**Follow-up analysis**

Among the 200 overweight/obese children undergoing clinical follow-up, 31 subjects (15%) developed IGR (n = 21 IFG, n = 4 IFG + IGT, n = 6 IGT) at the 6.5 (3.5–10) year evaluation.

Characteristics of this study subgroup at the baseline and follow-up are illustrated in Table 3.

Baseline SPISE index inversely correlated with age, BMI, SDS–BMI% and waist circumference at the follow-up. Having a lower SPISE index at baseline was associated with the development of higher blood pressure levels, impaired glucose and lipid profile at the follow-up evaluation (Table 4).

Belonging to the lowest quartile of the SPISE index distribution (i.e. SPISE index below 6.08) at baseline was associated with the development of IGR later in life with OR = 3.89 (1.65–9.13); \( \beta = 1.36; p = 0.002 \), at the multivariate logistic regression analysis adjusted for age, sex, fasting and 120 min glucose and insulin levels at baseline. The SPISE index showed high specificity and sensitivity in predicting future IGR, with AUROC curve = 0.82(0.72–0.92), \( p < 0.001 \) in the adjusted AUROC model corrected for the same covariates (Fig. 2).

Notably, unlike SPISE, neither ISI nor HOMA-IR at baseline were able to predict the development of IGR in obese children later in life in multivariate logistic regression models adjusted for sex, age and BMI [ISI: OR = 0.94

---

### Table 1 Baseline clinical characteristics of the whole study population in relation to the presence of overweight/obesity and impaired glucose metabolism

|                          | Overweight/obese children \( n = 909 \) | Overweight/obese NGT \( n = 813 \) | Overweight/obese IGR \( N = 96 \) | Normal weight children \( n = 99 \) | \( p \) value |
|--------------------------|----------------------------------------|------------------------------------|-----------------------------------|-------------------------------------|--------------|
| Age (years)              | 10.3 ± 3.2                             | 10.2 ± 3.2                         | 10.7 ± 3                          | 10.5 ± 3.3                         | 0.16° 0.59°  |
| Gender (M/F)             | 433/476                                | 381/432                            | 51/45                             | 56/43                              | 0.23°0.08°   |
| BMI (kg/m\(^2\))         | 27.4 ± 4.4                             | 27.3 ± 4.5                         | 28.3 ± 4.3                        | 17.5 ± 2.8                         | 0.04°        |
| SDS BMI                  | 2.05 ± 0.4                             | 2.05 ± 0.4                         | 2.1 ± 0.4                         | −0.48 ± 0.8                        | 0.46°        |
| Total cholesterol (mg/dL)| 166.8 ± 32                             | 166 ± 31.6                         | 175.2 ± 31.5                      | 164.8 ± 28.4                       | 0.007°       |
| HDL-C (mg/dL)            | 51.4 ± 12.3                            | 51.6 ± 12.3                        | 49.7 ± 12.5                       | 60.2 ± 12.4                        | 0.15°        |
| LDL-C (mg/dL)            | 102.6 ± 28                             | 103 ± 27.6                         | 109.8 ± 29                        | 95.2 ± 25.4                        | 0.008°       |
| Triglycerides (mg/dL)    | 62.8 ± 37.8                            | 60.8 ± 36.4                        | 78.5 ± 45                         | 47.2 ± 30.9                        | <0.001°      |
| FBG (mg/dL)              | 90 ± 7.3                               | 87.7 ± 5.8                         | 99.6 ± 9.7                        | 87.7 ± 8.6                         | <0.001°      |
| FSI (IU/mL)              | 15 ± 9.1                               | 14.6 ± 9                           | 17.9 ± 10.2                       | 11.4 ± 5.9                         | 0.003°       |
| 120 min BG (mg/dL)       | 105.3 ± 17.7                           | 102.7 ± 14.8                       | 126.3 ± 24.5                      | –                                   | <0.001°      |
| 120 min insulin (IU/ml)  | 61.5 ± 47.4                            | 58.2 ± 44.3                        | 89.2 ± 61.2                       | –                                   | <0.001°      |
| SPISE                    | 6.9 ± 1.6                              | 7 ± 1.6                             | 6.3 ± 1.7                         | 13.7 ± 2.9                         | <0.001°      |
| ISI                      | 6.9 ± 5.5                              | 7.1 ± 5.6                           | 4.6 ± 3.9                         | 12.4 ± 6.8                         | <0.001°      |
| HOMA-IR                  | 3.3 ± 2.1                              | 3.2 ± 2                             | 4.4 ± 2.5                         | 2.5 ± 1.4                          | <0.001°      |
| HOMA-β%                  | 148 ± 61.1                             | 220.5 ± 138                        | 186.5 ± 124.8                     | 125.5 ± 42.3                       | 0.002°       |
| NGT, number (%)          | 813 (89.4%)                            | 813 (100%)                          | 0                                  | 99 (100%)                          | <0.001°      |
| IFG                      | 65                                     | 0                                   | 65 (68%)                          | 0                                  |              |
| IGT                      | 27                                     | 0                                   | 27 (28%)                          | 0                                  |              |
| IFG + IGT                | 4                                      | 0                                   | 4 (4%)                            | 0                                  |              |
| DM                       | 0                                      | 0                                   |                                    | 0                                  |              |

Data are mean ± SD unless otherwise indicated. Differences have been compared by Student’s T test or \( \chi^2 \) test, as appropriate  
*BMI body mass index, SDS BMI standard deviation score of body mass index, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBG fasting blood glucose, FSI fasting serum insulin, HOMA-IR homeostasis model assessment of insulin resistance, HOMA-β% homeostasis model assessment of insulin secretion, ISI insulin sensitivity index, SPISE single-point insulin sensitivity estimator, TG/HDL triglycerides to HDL ratio, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus  
°Comparison between overweight/obese NGT vs overweight/obese IGR children  
^Comparison between overweight/obese and normal-weight children
Discussion

The main finding of this study is that the SPISE index correlates with insulin-derived indicators of insulin resistance and sensitivity in children, and significantly predicts the development of glucose metabolism abnormalities later in life in this population.

Indeed, on one hand, the SPISE index displayed a strong cross-sectional correlation with dynamic OGTT-derived indicators of insulin sensitivity such as ISI, or with the widely used proxy of insulin resistance HOMA-IR. On the other, low basal SPISE was able to predict the development of impaired glucose regulation at the 6.5-year follow-up with an OR of 3.89 (1.65–9.13) regardless of major metabolic confounders such as sex, age, and results from the OGTT performed at the baseline. At variance with SPISE, in our study, all the other insulin-derived indexes of insulin sensitivity/resistance calculated at baseline failed to demonstrate any correlation with future onset of IGR in children with body weight excess.

This is the first study aiming to test the reliability of the SPISE index as an indicator of insulin sensitivity in children and to assess its predictive value for the identification of glucose-insulin metabolism disorders later in life.

In the cross-sectional phase of this study, the association between the SPISE index and the OGTT-derived ISI, a validated indirect indicator of low insulin sensitivity also applied in children and adolescents [34, 35] was demonstrated in over 900 youths with body weight excess and was then confirmed in normal-weight children.

A number of studies previously investigated the relationship between the SPISE index and insulin-derived indicators of insulin homeostasis [23, 24, 36–39]; data showed that the SPISE index was comparable to Matsuda-ISI, QUICKI and HOMA-IR when used for the identification of conditions of altered insulin sensitivity in adults [23]. Moreover, lower SPISE index significantly correlated in adults or adolescents with the presence of T2D [36], metabolic syndrome [37, 39], risk of cardiovascular diseases [36], non-alcoholic

Table 2 Overweight/obese children population (n=909)

| Correlation coefficient | p value |
|-------------------------|---------|
| Age                     | −0.57   | <0.001 |
| SDS BMI                 | −0.56   | <0.001 |
| FBG                     | −0.16   | <0.001 |
| FSI                     | −0.43   | <0.001 |
| 120 min BG              | −0.11   | <0.001 |
| 120 min insulin         | −0.36   | <0.001 |
| Total cholesterol       | −0.007  | 0.82   |
| LDL-C                   | −0.03   | 0.35   |
| ISI                     | 0.45    | <0.001 |
| DI                      | 0.17    | <0.001 |
| HOMA-IR                 | −0.43   | <0.001 |
| HOMA-β                  | −0.35   | <0.001 |
| SBP                     | −0.55   | <0.001 |
| DBP                     | −0.42   | <0.001 |

Bivariate correlation analyses between SPISE index and clinical parameters; Pearson’s correlation coefficient

BMI body mass index, SDS BMI standard deviation score of body mass index, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBG fasting blood glucose, FSI fasting serum insulin, HOMA-IR homeostasis model assessment of insulin resistance, HOMA-β% homeostasis model assessment of insulin secretion, ISI insulin sensitivity index, DI disposition index, SBP systolic blood pressure, DBP diastolic blood pressure

(0.87–1.02), p = 0.12; HOMA-IR: OR 1.07 (0.85–1.34), p = 0.57]
fatty liver disease (NAFLD)\[38\], abdominal obesity, higher levels of C-reactive protein (CRP) and lower levels of adiponectin\[24\].

Finally, in line with our results obtained in youths, Sagasesaka et al. demonstrated that basal SPISE index was significantly lower in adults who developed T2D 10 years later in comparison to those who did not progress to diabetes, in a longitudinal investigation on over 27,000 individuals without diabetes \[40\].

Our study is the first investigation testing the SPISE index in children. The rise of childhood obesity in Western countries is paralleled by the increasing prevalence of T2D and other metabolic diseases such as NAFLD and metabolic syndrome in children and pre-adolescents \[41, 42\], as a significant proportion of overweight/obese children is also affected by subclinical-insulin resistance \[16, 18, 19\].

Therefore, identifying an easy, reliable and cost-effective tool for the stratification of cardio-metabolic risk in youths with body weight excess is a primary goal to achieve for

### Table 3

Characteristics of the subgroup of overweight/obese children \(n = 200\) undergoing 6.5 year follow-up (baseline and end of observation)

| Parameter                  | Baseline \(n = 200\) | Follow-up \(n = 200\) | \(p\) value |
|----------------------------|-----------------------|------------------------|-------------|
| Age (years)                | 9.58 ± 3.1            | 16.4 ± 3.7             | < 0.001     |
| BMI (kg/m²)                | 26.48 ± 3.9           | 29.63 ± 5.9            | < 0.001     |
| SDS BMI                    | 1.95 ± 0.3            | 1.88 ± 1.01            | 0.37        |
| SBP (mmHg)                 | 104.15 ± 13.5         | 114.89 ± 11.6          | < 0.001     |
| DBP (mmHg)                 | 61.01 ± 8.5           | 70.98 ± 8.3            | < 0.001     |
| Total cholesterol (mg/dL)  | 167.5 ± 33.1          | 172.21 ± 34.8          | 0.043       |
| HDL-C (mg/dL)              | 51.76 ± 12.6          | 50.69 ± 12.3           | 0.28        |
| LDL-C (mg/dL)              | 103.26 ± 28.9         | 104.90 ± 28.9          | 0.36        |
| Triglycerides (mg/dL)      | 58.76 ± 32.5          | 82.03 ± 39.7           | < 0.001     |
| FBG (mg/dL)                | 88.64 ± 7.3           | 88.64 ± 9.8            | 0.99        |
| FSI (IU/mL)                | 13.39 ± 8.7           | 15.24 ± 10.96          | 0.08        |
| 120 min glucose (mg/dL)    | 105.06 ± 17.4         | 99.52 ± 21.9           | 0.003       |
| 120 min insulin (mg/dL)    | 55.74 ± 43.6          | 68.74 ± 52.2           | 0.007       |
| SPISE                      | 7.29 ± 1.7            | 6.01 ± 1.9             | < 0.001     |
| ISI                        | 7.86 ± 5.9            | 6.37 ± 3.8             | 0.009       |
| DI                         | 74.06 ± 42.1          | 82.24 ± 61.99          | 0.13        |
| HOMA-IR                    | 2.96 ± 1.99           | 3.36 ± 2.6             | 0.11        |
| HOMA-%                     | 197.49 ± 137.8        | 249.52 ± 202.9         | 0.005       |

Data are mean ± SD unless otherwise indicated. Differences compared by Student’s \(T\) test. \(BMI\) body mass index, \(SDS BMI\) standard deviation score of body mass index, \(SBP\) systolic blood pressure, \(DBP\) diastolic blood pressure, \(HDL-C\) high-density lipoprotein cholesterol, \(LDL-C\) low-density lipoprotein cholesterol, \(FBG\) fasting blood glucose, \(FSI\) fasting serum insulin, \(SPISE\) single-point insulin sensitivity estimator, \(ISI\) insulin sensitivity index, \(DI\) disposition index, \(HOMA-IR\) homeostasis model assessment of insulin resistance, \(HOMA-%\) homeostasis model assessment of insulin secretion.

### Table 4

Bivariate correlation analyses between baseline SPISE and clinical parameters at the follow-up; Pearson’s coefficient

| Parameter                  | Correlation coefficient | \(p\) value |
|----------------------------|-------------------------|-------------|
| Age                        | −0.60                   | < 0.001     |
| SBP                        | −0.58                   | < 0.001     |
| DBP                        | −0.47                   | < 0.001     |
| BMI                        | −0.45                   | < 0.001     |
| SDS BMI                    | −0.31                   | 0.001       |
| Waist circumference        | −0.57                   | < 0.001     |
| FBG                        | −0.42                   | < 0.001     |
| 120 min BG                 | −0.12                   | 0.11        |
| FSI                        | −0.05                   | 0.53        |
| 120 min insulin            | −0.12                   | 0.11        |
| Total cholesterol          | −0.16                   | 0.02        |
| HDL-C                      | 0.12                    | 0.07        |
| LDL-C                      | −0.14                   | 0.04        |
| Triglycerides              | −0.29                   | < 0.001     |
| HOMA-IR                    | −0.12                   | 0.11        |
| HOMA-%                     | 0.19                    | 0.009       |
| ISI                        | −0.01                   | 0.90        |
| DI                         | 0.31                    | < 0.001     |

\(SBP\) systolic blood pressure, \(DBP\) diastolic blood pressure, \(BMI\) body mass index, \(SDS BMI\) standard deviation score of body mass index, \(FBG\) fasting blood glucose, \(FSI\) fasting serum insulin, \(HDL-C\) high-density lipoprotein cholesterol, \(LDL-C\) low-density lipoprotein cholesterol, \(HOMA-IR\) homeostasis model assessment of insulin resistance, \(HOMA-%\) homeostasis model assessment of insulin secretion, \(ISI\) insulin sensitivity index, \(DI\) disposition index.

---

Fig. 2. AUROC of the SPISE index for the prediction of IGR at the follow-up.
containing the burden of T2D and other metabolic complications of obesity across the new generations[43]. Indeed, although the euglycaemic-hyperinsulinaemic clamp represents the “gold standard” for measuring insulin sensitivity[44], this technique is invasive, expensive and difficult to perform in the clinical practice.

Thus, surrogate indexes of insulin resistance have been developed [23, 31–33]. Some of these include insulin or glucose loading and their measurement in determined time intervals, such as the Matsuda index, intravenous glucose tolerance test (IVGTT), insulin tolerance test (ITT)[45]. Other indexes consist in the measurement of insulin levels in a steady state (including HOMA-IR, QUICKI, HOMA, HOMA-1%S, etc.) [45–47]. However, the value of insulin measurement and insulin-derived indicators for metabolic risk stratification in the young population is still debated, and their interpretation is not univocal due to the pulsatility in insulin release [20], its short half-life [22] and the presence of poorly standardized assays [21].

In this setting, the identification of SPISE, a lipids and BMI derived index of insulin sensitivity, as a novel predictor of impaired glucose-insulin metabolism, provides a unique tool to be used in clinical practice for phenotyping children at high risk of metabolic diseases, such as those with obesity. Moreover, since insulin measurement is not advised for screening insulin resistance in large groups or for preventive purposes [16], whereas most of the population-based health surveys include BMI and lipid profile [23], the SPISE index may also be used as a sensitive and easy method to assess insulin sensitivity at the population level.

The SPISE index has been validated in a cross-sectional investigation including a large cohort of over 1200 nondiabetic adults and 29 obese adolescents [23]. In this study, a cut-off value of SPISE below 6.61 was proposed to indicate the presence of insulin resistance, as estimated by the comparison with the clamp-derived M value.

Conversely, our study is the first investigation exploring the SPISE index in the prediction of impaired glucose regulation development in overweight and obese children. Thus, rather than using a previously identified SPISE cut-off obtained in a non-comparable population and study design, in our study we explored whether belonging to the lowest quartile of the SPISE index distribution, i.e. SPISE below 6.08, at baseline was associated with the development of altered glucose metabolism. Thus, a SPISE index cut-off < 6.08 may be proposed as a novel threshold for low insulin sensitivity in children which could predict the development of dysglycaemia later in life in the setting of the real world evidence.

The rationale of the SPISE index to identify insulin resistance is particularly intriguing: TG and HDL represent changes in lipids and lipoproteins that are among the earliest manifestations of insulin resistance [48–50]. Indeed, insulin resistance measured by euglycaemic clamp is associated with adverse lipid and lipoprotein changes favoring atherosclerosis even in subjects without diabetes. The addition of BMI, another easy indirect measure of adipose tissue and insulin sensitivity, further enhances the sensitivity of the SPISE index. For all these characteristics, the SPISE index, but not traditional insulin-derived indicators of insulin sensitivity/resistance such as ISI and HOMA-IR, performed very well as a strong independent predictor of development of IGR in the large population of overweight and obese children included in this study.

In conclusion, this study demonstrates that the SPISE index is a strong indicator of insulin sensitivity in children with and without body weight excess, and that in overweight/obese individuals it predicts the development of impaired glucose regulation later in life independently from potential confounders. Finally, for its characteristics of non-invasive, low-cost and simple to estimate index, the SPISE index may represent an easy surrogate of insulin sensitivity in overweight/obese children to be used as a screening tool for metabolic risk assessment on a large scale.

Funding Open access funding provided by Università degli Studi dell’Aquila within the CRUI-CARE Agreement. This work was supported by Research Grants from the Department MeSVA, University of L’Aquila (Bando Ricerca FFO 2020 and FFO 2021) to Marco G. Baronci, Sapienza University of Rome “Ricerca Ateneo” to M.G.Cavallo. Ilaria Barchetta is supported by a Grant from Eli Lilly Foundation.

Availability of data and material The authors agree to share data upon request.

Declarations

Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed written consent was obtained.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA 307:483–490. https://doi.org/10.1001/jama.2012.40

2. Garrido-Migue M, Oliveira A, Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP, Soriano-Cano A et al (2019) Prevalence of overweight and obesity among European preschool children: a systematic review and meta-regression by food group consumption. Nutrients. https://doi.org/10.3390/nu11071698

3. Berenson GS (2012) Health consequences of obesity. Pediatr Blood Cancer 58:117–121. https://doi.org/10.1002/pbc.23373

4. Hamilton D, Dee A, Perry JJ (2018) The lifetime costs of overweight and obesity in childhood and adolescence: a systematic review. Obes Rev 19:452–463. https://doi.org/10.1111/obr.12649

5. Fang X, Zuo J, Zhou J, Cai J, Chen C, Xiang E et al (2019) Child and childhood obesity leads to adult type 2 diabetes and coronary artery diseases: A 2-sample Mendelian randomization study. Medicine. https://doi.org/10.1097/MD.0000000000016825

6. Goran MI, Ball GDC, Cruz ML (2003) Cardiovascular endocrinology: 2: Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 88:1417–1427. https://doi.org/10.1210/jc.2002-021442

7. Hagman E, Besor O, Hershkop K, Santoro N, Pierpont B, Mata M et al (2019) Relation of the degree of obesity in childhood to adipose tissue insulin resistance. Acta Diabetol 56:219–226. https://doi.org/10.1007/s00592-018-01285-3

8. Laakso M, Kuusisto J (2014) Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol 10:293–302. https://doi.org/10.1038/nrendo.2014.29

9. Valayapathi B, Gower B, Ashraf AP (2019) Pathophysiology of type 2 diabetes in children and adolescents. Curr Diabetes Rev 15:220–229. https://doi.org/10.2174/1573399814666180608074510

10. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, et al. (2006) Metabolic aspects of insulin resistance in individuals born small for gestational age. Horm Res Paediatr 65:137–143. https://doi.org/10.1159/000091519

11. Fang X, Zuo J, Zhou J, Cai J, Chen C, Xiang E et al (2019) Child and childhood obesity leads to adult type 2 diabetes and coronary artery diseases: A 2-sample Mendelian randomization study. Medicine. https://doi.org/10.1097/MD.0000000000016825

12. Vaag A, Bjorn Jensen C, Poulsen P, Bruns C, Pilgaard K, Grunnet L et al (2006) Metabolic aspects of insulin resistance in individuals born small for gestational age. Horm Res Paediatr 65:137–143. https://doi.org/10.1159/000091519

13. Ong YY, Badanathan SA, Aris IM, Tint MT, Yuan WL, Huang JY et al. (2020) Mismatch between poor fetal growth and rapid postnatal weight gain in the first 2 years of life is associated with higher blood pressure and insulin resistance without increased adiposity in childhood: The GUSTO cohort study. Int J Epidemiol 49:1591–1603. https://doi.org/10.1093/ije/dya1143

14. Payal V, Jora R, Sharma P, Gupta P, Gupta M (2016) Premature birth and insulin resistance in infancy: a prospective cohort study. Indian J Endocrinol Metab 20:497–505. https://doi.org/10.4103/2230-8210.183470

15. Rogers JM (2019) Smoking and pregnancy: epigenetics and developmental origins of the metabolic syndrome. Birth Defects Res 111:1259–1269. https://doi.org/10.1002/bdr2.1550

16. Levy-Marchal C, Arslanian S, Cutfield W, Sinaiko A, Druet C, Marcovcevich ML et al (2010) Insulin resistance in children: consensus, perspective, and future directions. J Clin Endocrinol Metab 95:5189–5198. https://doi.org/10.1210/jc.2010-1047

17. Romualdo MCDS, De Nóbrega FJ, Escrivão MAMS (2014) Insulin resistance in obese children and adolescents. J Pediatr 90:600–607. https://doi.org/10.1016/j.jsped.2014.03.005

18. Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG (2006) Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care 29:2427–2432. https://doi.org/10.2337/dc06-0709

19. Chiarelli F, Marcovcevich ML (2008) Insulin resistance and obesity in childhood. Eur J Endocrinol. https://doi.org/10.1530/EJE-08-0245

20. Hellman B (2009) Pulsatility of insulin release a clinically important phenomenon. Ups J Med Sci 114:193–205. https://doi.org/10.3109/0007939093660075

21. Marcovina S, Bowsher RR, Miller WG, Staten M, Myers G, Caudill SP et al (2007) Standardization of insulin immunoeasays: report of the American Diabetes Association Workgroup. Clin Chem 53:711–716. https://doi.org/10.1373/clinchem.2006.082214

22. Duckworth WC, Bennett RG, Hames FL (1998) Insulin degradation: progress and potential. Endocr Rev 19:608–624. https://doi.org/10.1210/edrv.19.5.0349

23. Paulmichl K, Hatunic M, Hsiľjund K, Jotic A, Krebs M, Mitrauk A et al (2016) Modification and validation of the triglyceride-to-HDL cholesterol ratio as a surrogate of insulin sensitivity in white juveniles and adults without diabetes mellitus: the single point insulin sensitivity estimator (SPISE). Clin Chem 62:1211–1219. https://doi.org/10.1373/clinchem.2016.257436

24. Correa-Burrows P, Blanco E, Gahagan S, Burrows R (2020) Validity assessment of the single-point insulin sensitivity estimator (spise) for diagnosis of cardiometabolic risk in post-pubertal Hispanic adolescents. Sci Rep 10:1–10. https://doi.org/10.1038/s41598-020-71074-y

25. Sentinelli F, Bertocciini L, Incani M, Pani MG, David F, Bailet D et al (2020) Association of apelin levels in overweight-obese children with pubertal development, but not with insulin sensitivity: 6.5 years follow up evaluation. Endocr Res 45:233–240. https://doi.org/10.1080/07435800.2020.1804929

26. Cambuli VM, Incani M, Pilia S, Congiu T, Cavallo MG, Cossu E et al (2009) Oral glucose tolerance test in Italian overweight/obese children and adolescents results in a very high prevalence of impaired fasting glycaemia, but not of diabetes. Diabetes Metab Res Rev 25:528–534. https://doi.org/10.1002/dmrr.980

27. American Diabetes Association (2021) 2 classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 44(Suppl 1):S15–S33. https://doi.org/10.2337/dc21-S002

28. Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L et al (2006) Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 29:581–593. https://doi.org/10.1007/BF03344156

29. Tanner JM (1986) 1 Normal growth and techniques of growth assessment. Clin Endocrinol Metab 15:411–451. https://doi.org/10.1007/978-3-662-03005-6

30. Muniyappa R, Lee S, Chen H, Quon MJ (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. https://doi.org/10.1152/ajpendo.00645.2007

31. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470. https://doi.org/10.2337/diacare.22.9.1462

32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin
concentrations in man. Diabetologia 28:412–419. https://doi.org/10.1007/BF00280883

33. U茨tschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ et al (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32:335–341. https://doi.org/10.2337/dc08-1478

34. George L, Bacha F, Lee SJ, Tfiyli H, Andreatta E, Arslanian S (2011) Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes. J Clin Endocrinol Metab 96:2136–2145. https://doi.org/10.1210/jc.2010-2813

35. Yeckel CW, Weiss R, Dziura J, Taksali SE, Dufour S, Burgert TS et al (2004) Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 89:1096–1101. https://doi.org/10.1210/jc.2003-031503

36. Cederholm J, Zethelius B (2019) SPISE and other fasting indexes of insulin resistance: risks of coronary heart disease or type 2 diabetes. Comparative cross-sectional and longitudinal aspects. Ups J Med Sci 124:265–272. https://doi.org/10.1080/03009734.2019.1680583

37. Dudi P, Goyal B, Saxena V, Rabari K, Mirza AA, Naithani M et al (2019) Single point insulin sensitivity estimator as an index for insulin sensitivity for metabolic syndrome: a study in North Indian population. J Lab Physicians 11:244–248. https://doi.org/10.4103/jlp.jlp_163_18

38. Miyakoshi T, Sagesaka H, Sato Y, Hiriehavashi K, Koike H, Yamashita K et al (2019) Reappraisal of attenuated insulin sensitivity in the evolution of non-alcoholic fatty liver disease. Eur J Clin Nutr 73:770–775. https://doi.org/10.1038/s41430-018-0246-3

39. Endukuru CK, Gaur GS, Yerrabelli D, Sahoo J, Vairappan B (2021) Cut-off values and clinical utility of surrogate markers for insulin resistance and beta-cell function to identify metabolic syndrome and its components among southern Indian adults. J Obes Metab Syndr 29:281–291. https://doi.org/10.7570/JOMES.20071

40. Sagesaka H, Sato Y, Someya Y, Tamura Y, Shimodaira M, Miyakoshi T et al (2018) Type 2 diabetes: when does it start? J Endocr Soc 2:476–484. https://doi.org/10.1210/js.2018-00071

41. Nobili V, Mantovani A, Cianfarani S, Alisi A, Mosca A, Sar-torelli MR et al (2019) Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. J Hepatol 71:802–810. https://doi.org/10.1016/j.jhep.2019.06.023

42. Serbis A, Giapros V, Kotanidou EP, Galli-Tsinopoulou A, Siomou E (2021) Diagnosis, treatment and prevention of type 2 diabetes mellitus in children and adolescents. World J Diabetes 12:344–365. https://doi.org/10.4239/wjd.v12.14.344

43. World Health Organization (2020) Noncommunicable diseases: Childhood overweight and obesity. https://www.who.int/news-room/q-a-detail/noncommunicable-diseases-childhood-overweight-and-obesity. Accessed on the 16 May 2021

44. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol. https://doi.org/10.1152/ajpendo.1979.237.3.e214

45. Tagi VM, Giannini C, Chiarelli F (2019) Insulin resistance in children. Front Endocrinol 10:342. https://doi.org/10.3389/fendo.2019.00342

46. Park SE, Park CY, Sweeney G (2015) Biomarkers of insulin sensitivity and insulin resistance: past, present and future. Crit Rev Clin Lab Sci 52:180–190. https://doi.org/10.3109/10408363.2015.1023429

47. Gutch M, Kumar S, Razi SM, Gupta K, Gupta A (2015) Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab 19:160–164. https://doi.org/10.4103/2230-8210.146874

48. Laakso M, Sarlund H, Mykkänen L (1990) Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arterioscler Thromb Vasc Biol 10:223–231. https://doi.org/10.1161/01.ATV.10.2.223

49. Di Bonito P, Paciﬁco L, Chiesa C, Valerio G, Miraglia Del Giudice E, Maffeis C et al (2017) Impaired fasting glucose and impaired glucose tolerance in children and adolescents with overweight/obesity. J Endocrinol Invest 40:409–416. https://doi.org/10.1007/s40618-016-0576-8

50. Di Bonito P, Moio N, Scilla C, Cavuto L, Sibilio G, Sanguigno E et al (2012) Usefulness of the high triglyceride-to-HDL cholesterol ratio to identify cardiometabolic risk factors and preclinical signs of organ damage in outpatient children. Diabetes Care 35:158–162. https://doi.org/10.2337/dc11-1456

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.